Cardiovascular Safety of Oral and Injectable Diabetes Medications
- Start Date:
- Tuesday, 31 October, 2017
- End Date:
- Tuesday, 31 October, 2017 11:00am
- Health & Nutrition
Training Options Duration: 60 Minutes Tuesday, October 31, 2017 | 10:00 AM PDT | 01:00 PM EDT Overview:This webinar will review the cardiovascular outcome trial data, evaluate the possible benefits and risks of therapy, and apply information to clinical practice. Why should you Attend: Diabetes affects 30.3 million Americans, which is approximately 9.4% of the population. Uncontrolled diabetes results in multiple microvascular and macrovascular complications, such as increased risk of heart disease, heart attack and stroke.
In 2015, diabetes remained the 7th leading cause of death in the United States. According to the American Diabetes Association and Centers for Disease Control, Atherosclerotic Cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality for individuals with diabetes. ASCVD is a large contributor to the health care costs of diabetes. Diabetes is an independent risk factor for cardiovascular disease, with many of those persons having elevated blood pressure and elevated lipid levels.
Therefore, it is essential to evaluate the cardiovascular safety of medications used to treat diabetes. There are several newer oral options for diabetes therapy, such as Dipeptidyl peptidase-4 (DPP-4) inhibitors and Sodium glucose cotransporter-2 (SGLT2) inhibitors; and injectable agents such as Glucagon-Like peptide-1 (GLP-1) receptor agonists. Various cardiovascular outcome trials evaluating oral and injectable diabetes medications have recently been published.
Areas Covered in the Session: Macrovascular and microvascular complications of uncontrolled diabetesReview of cardiovascular outcome trials for oral diabetes medicationsReview of cardiovascular outcome trials for injectable diabetes medications Who Will Benefit:PhysiciansDiabetes EducatorsNursesPharmacists Speaker Profile Daphne Smith Marsh is a Doctor of Pharmacy and Certified Diabetes Educator, who currently is a Clinical Pharmacist and Clinical Assistant Professor at the University of Illinois College of Pharmacy in Chicago.
Her clinical experience for the past 16 years includes provision of chronic disease education and co-management in the Internal Medicine, Endocrinology, Medication Therapy Management and Mile Square Health Clinics. Dr. Smith Marsh has been an invited speaker for national organizations, and has published in peer-reviewed national and international journals. Her research interests include diabetes education and medication adherence, particularly in the African American and Hispanic communities. Price - $139Contact Info:Netzealous LLC -MentorHealthPhone No: 1-800-385-1607Fax: 302-288-6884 Email: firstname.lastname@example.orgWebsite: http://www.mentorhealth.com/Webinar Sponsorship: https://www.mentorhealth.com/control/webinar-sponsorship/
Conference organized by NetZealous LLC-MentorHealth
This lesson will be addressing how law firms who work with protected health information need to get their HIPAA house in order as HIPAA is now fully enforced and the government is not using kid gloves any more
- 161 Mission Falls Lane, Suite 216